US

Eisai, a pharmaceutical company, announced promising initial results in a clinical trial for an injectable version of the Alzheimer’s drug Leqembi. This development brings hope for a more convenient option for administering this antibody treatment. Currently, the approved method for administering Leqembi is through intravenous infusion. However, Eisai and its partner Biogen seek approval for
0 Comments
The debate around net neutrality, the principle that all internet traffic should be treated equally without blocking or throttling, has resurfaced with renewed vigor. The Federal Communications Commission (FCC) recently voted in favor of initiating the process to reinstate the open internet rules, signaling a potential shift back to the safeguards established by the Obama
0 Comments